NCT01108055

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

A Phase II Study of Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Sandy Srinivas · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor) called pazopanib which is being studied in kidney cancer will be combined with standard chemotherapy called taxol in patients with relapsed recurrent urothelial cancer.

Detailed description

Based on the results from the Phase 1 study of pazopanib combined with paclitaxel and the activity of paclitaxel in urothelial cancer, testing this regimen in a disease where there is an unmet need appears appropriate.

Conditions

• Bladder Cancer
• Bladder (Urothelial, Transitional Cell) Cancer
• Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
• Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
• Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable

Interventions

Type	Name	Description
DRUG	Pazopanib (GW786034)	Cycle of 28 days. Pazopanib: 800mg/day
DRUG	Paclitaxel	Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15

Timeline

• Start date: 2010-04-01
• Primary completion: 2015-01-01
• Completion: 2015-07-01
• First posted: 2010-04-21
• Last updated: 2017-06-09
• Results posted: 2017-06-09

Locations

2 sites across 1 country: United States